EMERGENT BIOSOLUTIONS INC. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↓-23.6% -$46M
$149M
Cost of Revenue↓-28.1% -$33M
$85M
Gross Profit
$161M
R&D↑+33.0% +$3M
$12M
SG&A↓-16.0% -$10M
$51M
D&A↓-9.6% -$3M
$24M
Operating Income↑+18.6% +$12M
$77M
EBITDA↓-9.6% -$3M
$24M
Interest Expense↓-0.7% -$100K
$15M
Interest Income
—
Other Income/Expense↓-104.3% -$90M
$-4M
Pretax Income↓-59.6% -$85M
$58M
Tax Provision↑+5.4% +$200K
$4M
Net Income↓-55.4% -$64M
$51M
Gross Margin
54.9%
Operating Margin↑+11.1pts
33.1%
Net Margin↓-16.9pts
22.2%
Effective Tax Rate↓-8.3pts
11.1%
Deferred Tax Assets
—
Deferred Tax Liabilities
$2M
DTA Valuation Allowance↓-2.9% -$9M
$310M
ETR (Continuing Operations)↑+69.5pts
36.5%
ETR Federal Statutory
21.0%
Operating Lease Cost↑+0.0% +$0
$200K
Pension Net Periodic Cost
—
Revenue YoY Variation↑+6.0pts
-23.6%
Income YoY Variation↓-108.0pts
18.6%
Revenue QoQ Variation↓-1.9pts
-35.7%
Income QoQ Variation↑+4549.6pts
4681.3%